Jie Tian, Yong-Ping Song, Gao-Chong Zhang, Shu-Fang Wang, Xiao-Xiang Chu, Ye Chai, Chun-Ling Wang, Ai-Li He, Feng Zhang, Xu-Liang Shen, Wei-Hua Zhang, Lin-Hua Yang, Da-Nian Nie, Dong-Mei Wang, Huan-Ling Zhu, Da Gao, Shi-Feng Lou, Ze-Ping Zhou, Guo-Hong Su, Yan Li, Jin-Ying Lin, Qing-Zhi Shi, Gui-Fang Ouyang, Hong-Mei Jing, Sai-Juan Chen, Jian Li, Jian-Qing Mi
PURPOSE: The synergistic effects of combining arsenic compounds with imatinib against chronic myeloid leukemia (CML) have been established using in vitro data. We conducted a clinical trial to compare the efficacy of the arsenic realgar-indigo naturalis formula (RIF) plus imatinib with that of imatinib monotherapy in patients with newly diagnosed chronic phase CML (CP-CML). METHODS: In this multicenter, randomized, double-blind, phase 3 trial, 191 outpatients with newly diagnosed CP-CML were randomly assigned to receive oral RIF plus imatinib (n = 96) or placebo plus imatinib (n = 95)...
April 11, 2024: Journal of Cancer Research and Clinical Oncology